Cancer Research The Future of Cancer Research: Science and Patient Impact  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 55, 817-822, February 15, 1995]
© 1995 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Irmer, G.
Right arrow Articles by Emons, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Irmer, G.
Right arrow Articles by Emons, G.

Expression of the Messenger RNAs for Luteinizing Hormone-releasing Hormone (LHRH) and Its Receptor in Human Ovarian Epithelial Carcinoma1

Gabriele Irmer, Christiane Bürger, Rolf Müller, Olaf Ortmann, Ursula Peter, Sham S. Kakar, Jimmy D. Neill, Klaus-Dieter Schulz and Günter Emons2

Department of Obstetrics and Gynecology [G. I., O. O., U. P., K-D. S., G. E.] and Institute for Molecular Biology and Tumor Research [C. B., R. M.], Philipps University, D-35033 Marburg, Germany, and Department of Physiology and Biophysics [S. S. K., J. D. N.], University of Alabama at Birmingham, Birmingham, Alabama 35294

Recently we reported the presence of specific high affinity binding sites for luteinizing hormone-releasing hormone (LHRH) and its analogues (Kd = 1.5 or 1.7 nM) in the human epithelial ovarian cancer cell lines EFO-21 and EFO-27. The proliferation of these cell lines was inhibited by nM concentrations of a LHRH agonist. This study was performed to ascertain whether these ovarian cancer cell lines produce LHRH and whether the high affinity LHRH binding site found previously was identical to the pituitary LHRH receptor. Significant amounts of immunoreactive LHRH were found in the extracts of both the EFO-21 cell line (449 ± 56 fmol/106 cells) and the EFO-27 line (409 ± 76 fmol/106 cells). LHRH bioactivity of these extracts, assessed in terms of release of luteinizing hormone by rat pituitary cells, was comparable to that of authentic LHRH. EFO-21 and EFO-27 cells expressed the mRNAs for both human LHRH and human LHRH receptor as assessed by reverse transcriptase-PCR using oligonucleotide primers according to published sequences. In addition, in eight of eight biopsy samples of human epithelial ovarian cancers we detected mRNA for LHRH, six of these specimens expressed the mRNA representing the LHRH receptor. These data support the concept that human epithelial ovarian cancers might have a local system based on LHRH to regulate cell proliferation. It is still obscure at present whether LHRH produced locally has a stimulatory, inhibitory, or no impact on the proliferation of ovarian cancer cells. However, exogenous LHRH agonists seem to have clear antiproliferative activity, probably mediated through LHRH receptors. This finding might provide the base for novel approaches in the therapy of epithelial ovarian cancer.

1 This study was supported by the Deutsche Forschungsgemeinschaft (SFB 215, B10) and Graduiertenkolleg "Zell- und Tumorbiologie" (Marburg, Germany), P. E. Kempkes Foundation (Marburg, Germany), and Ferring Arzneimittel (Kiel, Germany), and by NIH Grant CA 60871.

2 To whom requests for reprints should be addressed, at Department of Obstetrics and Gynecology, Philipps-University, Pilgrimstein 3, D-35033 Marburg, Germany.

Received 6/28/94. Accepted 12/ 7/94.




This article has been cited by other articles:


Home page
Cancer Res.Home page
S. Fister, A. R. Gunthert, G. Emons, and C. Grundker
Gonadotropin-Releasing Hormone Type II Antagonists Induce Apoptotic Cell Death in Human Endometrial and Ovarian Cancer Cells In vitro and In vivo
Cancer Res., February 15, 2007; 67(4): 1750 - 1756.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. W.T. Cheung, P. C.K. Leung, and A. S.T. Wong
Gonadotropin-Releasing Hormone Promotes Ovarian Cancer Cell Invasiveness through c-Jun NH2-Terminal Kinase-Mediated Activation of Matrix Metalloproteinase (MMP)-2 and MMP-9.
Cancer Res., November 15, 2006; 66(22): 10902 - 10910.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
K.-Y. Kim, K.-C. Choi, N. Auersperg, and P. C K Leung
Mechanism of gonadotropin-releasing hormone (GnRH)-I and -II-induced cell growth inhibition in ovarian cancer cells: role of the GnRH-I receptor and protein kinase C pathway.
Endocr. Relat. Cancer, March 1, 2006; 13(1): 211 - 220.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
C. Leuschner and W. Hansel
Targeting Breast and Prostate Cancers Through Their Hormone Receptors
Biol Reprod, November 1, 2005; 73(5): 860 - 865.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
N. Eicke, A. R Gunthert, V. Viereck, D. Siebold, M. Behe, T. Becker, G. Emons, and C. Grundker
GnRH-II receptor-like antigenicity in human placenta and in cancers of the human reproductive organs
Eur. J. Endocrinol., October 1, 2005; 153(4): 605 - 612.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
J. C. Reubi
Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy
Endocr. Rev., August 1, 2003; 24(4): 389 - 427.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
X. Tang, T. Yano, Y. Osuga, H. Matsumi, N. Yano, J. Xu, O. Wada, K. Koga, K. Kugu, O. Tsutsumi, et al.
Cellular Mechanisms of Growth Inhibition of Human Epithelial Ovarian Cancer Cell Line by LH-Releasing Hormone Antagonist Cetrorelix
J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3721 - 3727.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
S. K. Kang, C.-J. Tai, P. S. Nathwani, K.-C. Choi, and P. C. K. Leung
Stimulation of Mitogen-Activated Protein Kinase by Gonadotropin-Releasing Hormone in Human Granulosa-Luteal Cells
Endocrinology, February 1, 2001; 142(2): 671 - 679.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
S. K. Kang, C.-J. Tai, P. S. Nathwani, and P. C. K. Leung
Differential Regulation of Two Forms of Gonadotropin-Releasing Hormone Messenger Ribonucleic Acid in Human Granulosa-Luteal Cells
Endocrinology, January 1, 2001; 142(1): 182 - 192.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. Gründker, K. Schulz, A. R. Günthert, and G. Emons
Luteinizing Hormone-Releasing Hormone Induces Nuclear Factor {kappa}B-Activation and Inhibits Apoptosis in Ovarian Cancer Cells
J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3815 - 3820.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
C.-T. Hsu, C.-Y. Ting, C.-J. Ting, T.-Y. Chen, C.-P. Lin, J. Whang-Peng, and J. Hwang
Vaccination against Gonadotropin-releasing Hormone (GnRH) Using Toxin Receptor-binding Domain-conjugated GnRH Repeats
Cancer Res., July 1, 2000; 60(14): 3701 - 3705.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
R. Grosse, A. Schmid, T. Schoneberg, A. Herrlich, P. Muhn, G. Schultz, and T. Gudermann
Gonadotropin-releasing Hormone Receptor Initiates Multiple Signaling Pathways by Exclusively Coupling to Gq/11 Proteins
J. Biol. Chem., March 24, 2000; 275(13): 9193 - 9200.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
P. Limonta, R. M. Moretti, M. M. Marelli, D. Dondi, M. Parenti, and M. Motta
The Luteinizing Hormone-Releasing Hormone Receptor in Human Prostate Cancer Cells: Messenger Ribonucleic Acid Expression, Molecular Size, and Signal Transduction Pathway
Endocrinology, November 1, 1999; 140(11): 5250 - 5256.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
I. Palyi, B. Vincze, S. Lovas, I. Mezo, J. Pato, A. Kalnay, G. Turi, D. Gaal, R. Mihalik, I. Peter, et al.
Gonadotropin-releasing hormone analogue conjugates with strong selective antitumor activity
PNAS, March 2, 1999; 96(5): 2361 - 2366.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Imai, A. Takagi, S. Horibe, H. Takagi, and T. Tamaya
Evidence for Tight Coupling of Gonadotropin-Releasing Hormone Receptor to Stimulated Fas Ligand Expression in Reproductive Tract Tumors: Possible Mechanism for Hormonal Control of Apoptotic Cell Death
J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 427 - 431.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
A. Nechushtan, S. Yarkoni, I. Marianovsky, and H. Lorberboum-Galski
Adenocarcinoma Cells Are Targeted by the New GnRH-PE66 Chimeric Toxin through Specific Gonadotropin-releasing Hormone Binding Sites
J. Biol. Chem., April 25, 1997; 272(17): 11597 - 11603.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1995 by the American Association for Cancer Research.